Stay updated with breaking news from Pick Disease. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A Disney song helps take Abby Alvey to another world where she's free of the stress and issues related to her terminal diagnosis of Niemann-Pick Disease (NPD).
Objectives: To determine the frequency of clinical presentation and laboratory profile in the diagnosis of the etiological spectrum of neonatal cholestasis. Material and methods: In this prospective cross-sectional study, we recruited children who presented with jaundice and direct hyperbilirubinemia with onset in the first three months of life. The study was conducted between April 2019 to March 2021 (24 months) at the Government Lady Reading Hospital of Khyber Pakhtunkhwa province in Pakistan. The diagnosis was based on history and clinical findings that included jaundice, stool color, it...
The "Europe Niemann-Pick Disease Market and Competitive Landscape 2021" report has been added to ResearchAndMarkets.com's offering. Europe Niemann-Pick Disease Market and Competitive Landscape 2021
FDA Grants Rare Pediatric Disease Designation to Polaryx Therapeutics’ Treatment for Niemann Pick Disease Share Rare Daily Staff The U.S. Food and Drug Administration granted Rare Pediatric Disease and Orphan Drug designations to Polaryx Therapeutics’ PLX-300 for the treatment of Niemann Pick Disease Types A and B. Niemann Pick Disease (NPD) Types A and B are a group of ultra-rare and fatal pediatric neurodegenerative disorders caused by defects in acid sphingomyelinase, a lysosomal enzyme which plays a pivotal role in the degradation of sphingomyelin. These genetic defect...
Share this article Share this article PARAMUS, N.J., Dec. 18, 2020 /PRNewswire/ -- Polaryx Therapeutics, Inc., a biotech company developing small molecule therapeutics for lysosomal storage disorders, announced today that it has received from the U.S. Food and Drug Administration (FDA) both Rare Pediatric Disease and Orphan Drug Designations for the treatment of Niemann Pick Disease Types A and B, known as Acid Sphingomyelinase Deficiency with PLX-300. Niemann Pick Disease (NPD) Types A and B is a group of ultra-rare and fatal pediatric neurodegenerative disorders caused by defects in ...